Optimal combination of antiangiogenic therapy for hepatocellular carcinoma

doi:10.4254/wjh.v7.i16.2029

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 16

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9115)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

492

WORD

223

HTML

4560

Tables (1-2)

574

Sum=5849

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1184

Download

2083

Sum=3267

Aug 8, 2015 (publication date) through Mar 3, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Hepatol. Aug 8, 2015; 7(16): 2029-2040
Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.2029

Optimal combination of antiangiogenic therapy for hepatocellular carcinoma

Hui-Ju Ch’ang

Hui-Ju Ch’ang, National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan

Hui-Ju Ch’ang, Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 100, Taiwan

Author contributions: Ch’ang HJ solely contributed to this manuscript.

Supported by National Health Research Institutes, Taiwan.

Conflict-of-interest statement: Nothing to declare.

Correspondence to: Hui-Ju Ch’ang, MD, National Institute of Cancer Research, National Health Research Institutes, R1-2034, 35, Keyen Road, Miaoli 35053, Taiwan. hjmc@nhri.org.tw

Telephone: +886-37-246166-35105 Fax: +886-37-586463

Received: July 29, 2014
Peer-review started: July 30, 2014
First decision: December 17, 2014
Revised: July 21, 2015
Accepted: July 24, 2015
Article in press: July 27, 2015
Published online: August 8, 2015
Processing time: 375 Days and 2.1 Hours

Core Tip

Core tip: Antiangiogenic therapy has become an important component of treatment in hepatocellular carcinoma (HCC) patients. However, traditional anatomic imaging of tumor shrinkage is not appropriate to evaluate the efficacy of antiangiogenesis achieved by normalizing tumor vasculature and systemic suppression of angiogenic and inflammatory cytokines. To identify and validate potential response biomarkers, standardized systemic, circulating, tissue and imaging assays should be incorporated in to preclinical and clinical studies regarding the combination of antiangiogenic agents to cytotoxic or biologic agents. The optimal dosage, schedule and duration of antiangiogenic during combination therapy for HCC patients should be titrated according to these response biomarkers.